Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2006-11-14
2006-11-14
Kishore, Gollamudi S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
Reexamination Certificate
active
07135192
ABSTRACT:
Angiogenic endothelial cells are selectively targeted with lipid/DNA complexes or cationic liposomes containing a substance which affects the targeted cells by inhibiting or promoting their growth. A site of angiogenesis can be precisely located by administering cationic liposomes containing a detectable label. The complexes may comprise nucleotide constructs which are comprised of promoters which are selectively and exclusively activated in the environment of an angiogenic endothelial cell.
REFERENCES:
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 5092885 (1992-03-01), Yamada et al.
patent: 5192744 (1993-03-01), Bouck et al.
patent: 5202352 (1993-04-01), Okada et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5556878 (1996-09-01), Kelly et al.
patent: 5580899 (1996-12-01), Mayhew et al.
patent: 5641755 (1997-06-01), Weichselbaum et al.
patent: 5770581 (1998-06-01), Weichselbaum et al.
patent: 5837283 (1998-11-01), McDonald et al.
patent: 5837682 (1998-11-01), Folkman et al.
patent: 5935937 (1999-08-01), Smith
patent: 5965739 (1999-10-01), Kelly et al.
patent: 6120799 (2000-09-01), McDonald et al.
patent: 6271206 (2001-08-01), Pillai
patent: 6426086 (2002-07-01), Papahadjopoulos
patent: 6756055 (2004-06-01), McDonald et al.
patent: 0 636 363 (1995-02-01), None
patent: 0819758 (1998-01-01), None
patent: WO 91/06309 (1991-05-01), None
patent: WO 91/16024 (1991-10-01), None
patent: WO 93/12240 (1993-06-01), None
patent: WO 93/12756 (1993-07-01), None
patent: WO 93/18751 (1993-09-01), None
patent: WO 93/24640 (1993-12-01), None
patent: WO 93/25673 (1993-12-01), None
patent: WO 95/25543 (1995-09-01), None
patent: WO 95/29242 (1995-11-01), None
patent: WO 95/29242 (1995-11-01), None
patent: WO 00/47235 (2000-08-01), None
Wasan, E. K., Plasmid DNA is protected against ultrasonic cavitation-induced damage when complexed to cationic liposomes., Journal of Pharmaceutical Sciences, 85, # 4, pp. 427-433, Apr., 1996.
Klauber, et al. “Inhibition of angiogenesis and breast cancer in mice be the microtubule inhibitors 2-methoxyestradiol and Taxol™”,CancerResearch, (1997) vol. 57: 81-86.
Isner, “Cancer and atherosclerosis: The broad mandate of angiogenesis”, Circulation, (1999) vol. 99(13): 1653-1655.
Campbell, et al., “Cationic liposome mediated drug delivery”,Biophys. J., (1997) vol. 72(2): A303 (WP313).
McLean, et al., “Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice”,Amer. J. Physiology. vol. 1, part 2, 273:H387-H404.
Brigham, K.L., et al., (1989) “Expression of a Prokaryotic Gene in Cultured Lung Endothelial Cells after Lipofection with a Plasmid Vector,” Am. J. Respir. Cell Mol. Biol. 1: 95-100.
Brigham, K.L., et al. (1989) “Rapid Communication: In vivo Transfection of Murine Lungs with a Functioning Prokaryotic Gene Using a Liposome Vehicle,” from the Center for Lung Research, Dept. of Med. Path. and Molecular Phys. and Biophys., Vanderbuilt U. School of Med., Nashville, Tenn. pp. 278-284.
Burrows, F.J., et al., (1993) “Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature,” Proc. Natl. Acad. Sci. USA 90: 8996-9000.
Felgner, P.L., et al., (1991) “Gene Therapeutics” Nature 349: 351-352.
Felgner, P.L., et al., (1987) “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure,” Proc. Natl. Acad. Sci. USA 84: 7413-7417.
Folkman, J., et al., (1989) “Induction of angiogenesis during the transition from hyperplasia to neoplasia,” Nature 339: 58-61.
Folkman, J., et al., (1987) “Angiogenic Factors,” Science 235:442-447.
Gao, X., et al., (1995) “Cationic liposome-mediated gene transfer,” Gene Therapy 2: 710-722.
Hanahan, D., et al., (1996) “Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis,” Cell 86: 353-364.
Huang, X., et al., (1997) “Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature,” Science 275: 547-550.
Morishita, K., et al., (1995) “A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-specific gene expression,” J. Biol Chem. 270: 27948-27953.
Xu, M., et al., “Parental Gene Therapy with p53 Inhibits Human Breast Tumors in Vivo Through a Bystander Mechanism Without Evidence of Toxicity,” Human Gene Therapy 8:177-185.
Iwona Wrobel, et al. Biochimica et Biophysica Acta, 1995, vol. 1235, p. 296-304.
Baulk Peter
McDonald Donald M.
McLean John
Thurston O. Gavin
Borden Paula A.
Bozicevic Karl
Bozicevic Field & Francis LLP
Kishore Gollamudi S.
The Regents of the University of California
LandOfFree
Cationic lipid compositions targeting angiogenic endothelial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cationic lipid compositions targeting angiogenic endothelial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cationic lipid compositions targeting angiogenic endothelial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3660711